This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Miocamycin
- DrugBank Accession Number
- DB13287
- Background
Miocamycin is a macrolide type antimicrobial 1. This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia 2. It has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections or as an alternative to erythromycin treatment 1.
- Type
- Biotech
- Groups
- Approved
- Synonyms
- Midecamycin acetate
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Bacterial sinusitis •••••••••••• Treatment of Biliary tract infection bacterial •••••••••••• Treatment of Bronchitis bacterial •••••••••••• Treatment of Pharyngitis bacterial •••••••••••• Treatment of Pneumonia, bacterial •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Miocamycin. Acalabrutinib The serum concentration of Acalabrutinib can be increased when it is combined with Miocamycin. Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Miocamycin. Acetyldigitoxin The serum concentration of Acetyldigitoxin can be increased when it is combined with Miocamycin. Albendazole The metabolism of Albendazole can be decreased when combined with Miocamycin. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- J01FA11 — Miocamycin
- Drug Categories
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antibacterials for Systemic Use
- Antiinfectives for Systemic Use
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)
- Cytochrome P-450 Enzyme Inhibitors
- Lactones
- Macrolides
- Macrolides, Lincosamides and Streptogramins
- Polyketides
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 3T48CPS7U2
- CAS number
- 55881-07-7
References
- General References
- Holliday SM, Faulds D: Miocamycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1993 Oct;46(4):720-45. doi: 10.2165/00003495-199346040-00008. [Article]
- Kegg Japanese Pharmacopoeia [Link]
- AIFA Product Information: Macroral (miocamycin) for oral use [Link]
- External Links
- ChemSpider
- 16735908
- 236200
- ChEMBL
- CHEMBL1091024
- ZINC
- ZINC000169677000
- Wikipedia
- Miocamycin
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Granule, for suspension Oral 250 MG/5ML Granule, for suspension Oral 300 MG Granule, for suspension Oral 600 MG Granule, for suspension Oral 900 MG Tablet, coated Oral 300 MG Tablet, coated Oral 600 MG Tablet Oral 300 MG - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Inhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. doi: 10.2165/00003088-200039030-00003. [Article]
Drug created at June 23, 2017 20:39 / Updated at October 27, 2020 21:12